Harmony Biosciences Holdings, Inc. (HRMY)
Largest Insider Buys in Sector
HRMY Stock Price History Chart
HRMY Stock Performance
About Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, …
Insider Activity of Harmony Biosciences Holdings, Inc.
Over the last 12 months, insiders at Harmony Biosciences Holdings, Inc. have bought $0 and sold $281.5M worth of Harmony Biosciences Holdings, Inc. stock.
On average, over the past 5 years, insiders at Harmony Biosciences Holdings, Inc. have bought $25.07M and sold $108.33M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,844 shares for transaction amount of $269,049 was made by Nielsen Jack (director) on 2020‑08‑26.
List of Insider Buy and Sell Transactions, Harmony Biosciences Holdings, Inc.
| 2024-11-05 | Sale | 10 percent owner | 600,000 0.9614% | $30.30 | $18.18M | +12.75% | ||
| 2024-11-05 | Sale | 10 percent owner | 600,000 0.9614% | $30.30 | $18.18M | +12.75% | ||
| 2024-11-01 | Sale | 10 percent owner | 4M 6.4248% | $30.30 | $121.21M | -0.09% | ||
| 2024-11-01 | Sale | 10 percent owner | 4M 6.4248% | $30.30 | $121.21M | -0.09% | ||
| 2024-10-29 | Sale | CHIEF COMMERCIAL OFFICER | 21,496 0.0369% | $40.47 | $870,018 | -20.31% | ||
| 2024-10-01 | Sale | CHIEF COMMERCIAL OFFICER | 400 0.0007% | $40.19 | $16,077 | -11.29% | ||
| 2024-09-30 | Sale | CHIEF COMMERCIAL OFFICER | 35,846 0.0635% | $40.03 | $1.43M | -12.95% | ||
| 2024-09-27 | Sale | CHIEF COMMERCIAL OFFICER | 200 0.0004% | $40.05 | $8,009 | -10.99% | ||
| 2024-03-15 | Sale | CHIEF COMMERCIAL OFFICER | 11,979 0.0211% | $32.00 | $383,328 | +1.63% | ||
| 2024-03-08 | Sale | CHIEF COMMERCIAL OFFICER | 194 0.0004% | $32.00 | $6,208 | +3.41% | ||
| 2022-12-14 | Sale | director | 2,834 0.0049% | $59.96 | $169,927 | -39.81% | ||
| 2022-12-14 | Sale | director | 130 0.0002% | $60.00 | $7,800 | -39.81% | ||
| 2022-12-13 | Sale | director | 6,320 0.0108% | $60.13 | $380,022 | -40.40% | ||
| 2022-12-12 | Sale | director | 22,391 0.038% | $60.36 | $1.35M | -41.12% | ||
| 2022-12-09 | Sale | director | 9,847 0.0169% | $59.89 | $589,737 | -40.08% | ||
| 2022-12-08 | Sale | director | 36,878 0.0624% | $59.90 | $2.21M | -40.84% | ||
| 2022-12-07 | Sale | director | 64,026 0.1088% | $60.35 | $3.86M | -40.94% | ||
| 2022-12-05 | Sale | director | 77,853 0.1323% | $61.23 | $4.77M | -41.65% | ||
| 2022-12-02 | Sale | CHIEF STRATEGY OFFICER | 38,000 0.0639% | $60.13 | $2.29M | -41.20% | ||
| 2022-12-01 | Sale | director | 65,652 0.1109% | $60.00 | $3.94M | -40.73% |
Insider Historical Profitability
| Marshman Fund Trust II | 10 percent owner | 6051120 10.6102% | $34.17 | 1 | 2 | <0.0001% |
| Novo Holdings A/S | 10 percent owner | 4409803 7.7323% | $34.17 | 1 | 0 | <0.0001% |
| Nielsen Jack | director | 2571024 4.5081% | $34.17 | 5 | 30 | <0.0001% |
Institutional Investor Ownership
| Valor Management Llc | $376.7M | 19.75 | 11.22M | 0% | +$0 | 78.55 | |
| BlackRock | $198.89M | 10.43 | 5.92M | -1.34% | -$2.71M | <0.01 | |
| Fidelity Investments | $176.48M | 9.25 | 5.26M | -0.4% | -$715,489.06 | 0.01 | |
| The Vanguard Group | $121.84M | 6.39 | 3.63M | -1.27% | -$1.56M | <0.01 | |
| Vivo Capital | $87.52M | 4.59 | 2.61M | 0% | +$0 | 7.62 |